Agenus Inc last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $31.5 million (+4.1% year over year) and diluted EPS of $0.02. It usually reports 36–75 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 15, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 16, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–75 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
31
+4.1%
|
3
-95.7%
|
0.02
-99.0%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
35
+34.4%
|
-1
+98.1%
|
-0.01
+99.0%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
34
+40.2%
|
39
+248.7%
|
1.02
+199.0%
|
|
Mar 16, 2026
75 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
34
+27.5%
|
-11
+77.3%
|
-0.31
+84.4%
|
|
Nov 10, 2025
41 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
30
+20.4%
|
64
+195.1%
|
1.94
+163.0%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
26
+9.3%
|
-30
+45.2%
|
-1.00
+60.3%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
24
-14.1%
|
-26
+58.4%
|
-1.03
+66.1%
|
|
Mar 11, 2025
70 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
27
-68.0%
|
-47
+3.7%
|
-2.01
+17.0%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lexington, MA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1098972
- Former names
- ANTIGENICS INC /DE/ (until Jan 5, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.